FDA 483 - Blount Discount Pharmacy, Inc. - February 13, 2020

This FDA Form 483 document details observations made during an inspection of a pharmaceutical manufacturing facility. The inspection identified four key deficiencies related to the firm's quality system and manufacturing processes for sterile drug products.

Observation 1 notes the firm's failure to establish an adequate system for monitoring environmental conditions within the aseptic processing area. This indicates a potential risk to the sterility of the drug products.

Observation 2 highlights that the sterilization process for equipment used in the production of sterile drug products was not adequately validated. This is a critical finding as it directly impacts the sterility assurance of the final product.

Observation 3 indicates that the firm did not conduct routine calibration of critical equipment used in the manufacturing process. Lack of calibration can lead to inaccurate measurements and potentially compromise product quality and consistency.

Finally, Observation 4 states that the firm lacked adequate procedures for the handling and storage of raw materials. This deficiency could lead to contamination, degradation, or misidentification of materials, impacting product quality.

These observations collectively suggest significant gaps in the firm's quality control and assurance systems, particularly concerning sterile manufacturing and material management. The business and operational implications include potential regulatory action, product recalls, and a need for substantial remediation efforts to address these critical deficiencies.